The Spectrum of Atherosclerotic Coronary Artery Disease in HIV Patients
- 140 Downloads
The incidence of HIV is on the rise. With the advent of antiretroviral therapy, the average life expectancy of HIV patients has increased by several decades, but the increasing life expectancy has shifted the spectrum of HIV-associated morbidity and mortality away from opportunistic infections and toward chronic medical conditions. In fact, coronary artery disease has become the leading cause of mortality in patients with HIV. The pathophysiology of atherosclerosis in patients with HIV is very complex, including direct endothelial damage from viremia, a heightened overall state of inflammation from immune activation, higher prevalence and contribution from traditional atherosclerotic risk factors, and direct effects from antiretroviral therapy itself. This review focuses on the patterns, predictors, and pathophysiology of atherosclerotic disease in patients with HIV. In addition, the risks and benefits of evidence-based highly active antiretroviral therapy are critically evaluated.
KeywordsHIV Atherosclerosis Coronary artery disease Highly Active Anti Retroviral Theraphy (HAART)
No potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 7.Currier JS, Taylor A, Boyd F, et al.: Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2004, 33:506–512.Google Scholar
- 14.Savès M, Chêne G, Ducimetière P, et al., for the French WHO MONICA Project and the APROCO (ANRS EP11) Study Group: Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003, 37:292–298.CrossRefPubMedGoogle Scholar
- 48.Dubé MP, Stein JH, Aberg JA, et al., for Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613–627.CrossRefPubMedGoogle Scholar